22 material Form 8-K filings that 21 companies we cover made with the SEC in August 2023, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Berkshire Hathaway reported second-quarter 2023 net earnings attributable to shareholders of $35.9 billion, compared with a net loss of $43.6 billion in the second quarter of 2022. Operating earnings, which exclude investment and derivative gains and losses, rose to $10.0 billion from $9.4 billion, and the company said it repurchased about $1.4 billion of its shares during the quarter.
Net earnings were $35.9 billion in Q2 2023 versus a $43.6 billion loss in Q2 2022; investment and derivative gains were $25.9 billion, compared with losses of $53.0 billion a year earlier.
Operating earnings were $10.0 billion in Q2 2023, up from $9.4 billion in Q2 2022.
Berkshire repurchased about $1.4 billion of its shares in Q2 2023, bringing the six-month total to $5.8 billion.
Insurance float was about $166 billion at June 30, 2023, up about $2 billion from year-end 2022.
Krystal Biotech disclosed that Andrew Orth, its Chief Commercial Officer, resigned and that his last day with the company was August 2, 2023. The filing does not give a reason for the departure or name a successor, and it does not describe any financial impact.
Andrew Orth, Chief Commercial Officer, resigned from his position.
Orth's last day with Krystal Biotech was August 2, 2023.
The filing does not name a replacement or state a reason for the resignation.
Krystal Biotech reported a second-quarter 2023 net loss of $33.2 million, or $(1.25) per share, up from $28.1 million, or $(1.10) per share, a year earlier. The filing reports no revenue figure; it cites 121 Patient Start Forms for VYJUVEK in the first six weeks after its May 19 FDA approval, and $505.9 million in cash, cash equivalents and investments at June 30, 2023.
Q2 2023 net loss was $33.2 million, or $(1.25) per share, versus $28.1 million, or $(1.10) per share, in Q2 2022.
General and administrative expenses rose to $25.9 million from $17.9 million, and R&D expenses rose to $12.1 million from $10.9 million.
As of June 30, the company had received 121 VYJUVEK Patient Start Forms, 30 of them for dominant dystrophic epidermolysis bullosa.
Cash, cash equivalents and investments totaled $505.9 million on June 30, 2023.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.